Intellia Therapeutics provided a clinical update at ESGCT on its in‑vivo LNP editing programs. CSO Birgit Schultes reported that NTLA‑2002 (lonvo‑z), an LNP‑delivered therapy for hereditary angioedema (HAE), reduced kallikrein levels to below 60% for durations extending beyond two years with only transient liver enzyme elevations reported. The company emphasized the liver‑targeting advantages of lipid nanoparticles—transient expression, redosing capability and scalable manufacturing—and noted more than 350 patients treated across Intellia programs with published clinical experience. The HAE program’s durable biomarker suppression and safety signals add confidence to the in‑vivo editing approach and inform regulatory and development plans for future indications.